ArticleAlzheimer's research & therapy2021
Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.
Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Testing the knowledge of Alzheimer's diseaseFrontiers in public health · 2022Trial
- Association of functional brain alterations with β-amyloid, tau, and cognitive decline in Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Blood pressure and Alzheimer's disease biomarkers in cognitively unimpaired adults: a multicenter study.The journal of prevention of Alzheimer's disease · 2025Observational
- Spatial and temporal patterns of cortical mean diffusivity in Alzheimer's disease and suspected non-Alzheimer's disease pathophysiology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Genetic architecture of hippocampus subfields volumes in Alzheimer's disease.CNS neuroscience & therapeutics · 2024Article
- The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
- Age-related and amyloid-beta-independent tau deposition and its downstream effects.Brain : a journal of neurology · 2023Article
- Based on Tau PET Radiomics Analysis for the Classification of Alzheimer's Disease and Mild Cognitive Impairment.Brain sciences · 2023Article
- Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer's disease.Alzheimer's research & therapy · 2023Article
- Clinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels.Frontiers in aging neuroscience · 2023Article
- Hypertension, Neurovascular Dysfunction, and Cognitive Impairment.Hypertension (Dallas, Tex. : 1979) · 2023Review
- Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2023Article
- A healthy mind in a healthy body: Effects of arteriosclerosis and other risk factors on cognitive aging and dementia.The psychology of learning and motivation · 2022Article
- The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.Journal of Alzheimer's disease : JAD · 2022Article
- Altered serum amyloid beta and cerebral perfusion and their associations with cognitive function in patients with subcortical ischemic vascular disease.Frontiers in neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundWe recently reported that CSF phosphorylated tau (p-Tau
methodsWe examined relationships between CSF p-Tau/Aβ
resultsElevated CSF p-Tau/Aβ
conclusionsThese data provide surprising clues as to the etiology and significance of tau pathology in the absence of Aβ. It seems likely that, in addition to age, both cerebrovascular disease and subthreshold levels of Aβ are related to this tau accumulation. Crucially, this phenotype of CSF tau elevation in amyloid-negative individuals share features with AD such as a pattern of metabolic decline and regional brain atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.